Amedeo Smart

Free Medical Literature Service

 

Amedeo

Inflammatory Bowel Diseases
  Free Subscription

Articles published in
Scand J Gastroenterol
    September 2025
  1. YE C, Li W, Li X, Jiang Q, et al
    Risk factors for mucosal cytomegalovirus infection and specific endoscopic features in patients with ulcerative colitis.
    Scand J Gastroenterol. 2025 Sep 19:1-11. doi: 10.1080/00365521.2025.2558970.
    >> Share

  2. HJELLE H, Myklebust TA, Granlund AVB, Ostvik AE, et al
    Changes in prevalence and incidence of inflammatory bowel disease over 30 years: a population-based cohort study, the HUNT study.
    Scand J Gastroenterol. 2025 Sep 12:1-11. doi: 10.1080/00365521.2025.2555920.
    >> Share

  3. HAANAPPEL AEG, van Tieghem de Ten Berghe C, Ali M, Wolthuis AM, et al
    Predictive value of postoperative CRP levels for endoscopic recurrence in patients with Crohn's disease undergoing ileocolic resection.
    Scand J Gastroenterol. 2025 Sep 10:1-9. doi: 10.1080/00365521.2025.2553885.
    >> Share

    August 2025
  4. LIM S, Kim KW, Moon JS, Kim SH, et al
    Tight monitoring with colonoscopy and magnetic resonance enterography improves outcomes in patients with Crohn's disease.
    Scand J Gastroenterol. 2025 Aug 22:1-12. doi: 10.1080/00365521.2025.2544307.
    >> Share

  5. BONFILS L, Dalsgaard LT, Poulsen GJ, Eld M, et al
    Validation of date of diagnosis and disease location of inflammatory bowel disease in the Danish National Patient Registry and the Danish Pathology Registry using a regional cohort.
    Scand J Gastroenterol. 2025 Aug 12:1-10. doi: 10.1080/00365521.2025.2544309.
    >> Share

  6. MARLICZ W, Skonieczna-Zydecka K, Loniewski I, Koulaouzidis A, et al
    Rethinking iron therapy in IBD: integrating the microbiota perspective.
    Scand J Gastroenterol. 2025;60:817-819.
    >> Share

    July 2025
  7. TAN YY, Cheong EHT, Lim CT, Cai S, et al
    Clinical and environmental impact of intestinal ultrasound for inflammatory bowel disease: a tertiary centre experience in Southeast Asia.
    Scand J Gastroenterol. 2025 Jul 23:1-11. doi: 10.1080/00365521.2025.2533338.
    >> Share

  8. LEHMANN V, Bastiaens D, Bosch J, Bennebroek Evertsz F, et al
    Sexual functioning in patients with inflammatory bowel diseases (IBD): prevalence, predictors, and potential benefits of cognitive behavioral therapy (CBT).
    Scand J Gastroenterol. 2025;60:707-715.
    >> Share

  9. PETTERSSON N, Kragbjerg F, Hamrin A, Forsblad-d'Elia H, et al
    Spondyloarthritis features in IBD patients: prevalence, referral trends and clinical implications. A questionnaire-based study.
    Scand J Gastroenterol. 2025;60:686-697.
    >> Share

    June 2025
  10. MADSEN GR, Bert K, Wahlin A, Najjar D, et al
    Periodontitis is associated with increased disease activity in a Swedish cohort of patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2025 Jun 14:1-17. doi: 10.1080/00365521.2025.2517217.
    >> Share

  11. STRANDE V, Hagen M, Lund C, Asak O, et al
    Predicting severe inflammatory bowel disease: a risk matrix model based on the IBSEN III inception cohort.
    Scand J Gastroenterol. 2025 Jun 8:1-12. doi: 10.1080/00365521.2025.2512591.
    >> Share

    May 2025
  12. NIELSEN MA, Bendix M, Hvas CL, Deleuran B, et al
    Increased mucosal and T-cell expression of 4-1BB and PD-1 are modulated by anti-TNFalpha treatment in Crohn's disease.
    Scand J Gastroenterol. 2025 May 24:1-9. doi: 10.1080/00365521.2025.2505622.
    >> Share

  13. DHARMADASA V, Yip Lundstrom LM, Khatibi N, Hossain J, et al
    Factors affecting response rates in patient-reported outcome measures in inflammatory bowel disease.
    Scand J Gastroenterol. 2025 May 10:1-14. doi: 10.1080/00365521.2025.2501070.
    >> Share

  14. MAURUD S, Lunde L, Moen A, Opheim R, et al
    Mapping conditional health literacy and digital health literacy in patients with inflammatory bowel disease to optimise availability of digital health information: a cross-sectional study.
    Scand J Gastroenterol. 2025 May 2:1-12. doi: 10.1080/00365521.2025.2497952.
    >> Share

  15. TIANEZE DE CASTRO C, da Silva Oliveira D, Freire de Melo F, Lima Barreto M, et al
    Global prevalence of biologic drugs use in inflammatory bowel diseases: a systematic review and meta-analysis.
    Scand J Gastroenterol. 2025;60:439-453.
    >> Share

    April 2025
  16. TUKEK NB, Bakkaloglu OK, Sen G, Hatemi I, et al
    The effects of biologics on ulcerative colitis-related colectomy rate: results of a 22-year study.
    Scand J Gastroenterol. 2025 Apr 29:1-10. doi: 10.1080/00365521.2025.2497954.
    >> Share

  17. BROMS G, Forss A, Eriksson J, Askling J, et al
    Adult-onset inflammatory bowel disease and the risk of venous thromboembolism - a Swedish nationwide cohort study 2007-2021.
    Scand J Gastroenterol. 2025 Apr 26:1-10. doi: 10.1080/00365521.2025.2488053.
    >> Share

  18. UPADHYAY KG, Desai DC, Ashavaid TF, Dherai AJ, et al
    Evaluating the role of kynurenine/tryptophan ratio as an indicator of disease activity in Indian patients with inflammatory bowel disease. A case-control study.
    Scand J Gastroenterol. 2025 Apr 11:1-9. doi: 10.1080/00365521.2025.2491784.
    >> Share

  19. DETLIE TE, Burisch J, Jahnsen J, Bonderup O, et al
    Iron deficiency should not be accepted in patients with inflammatory bowel disease - a Scandinavian expert opinion.
    Scand J Gastroenterol. 2025 Apr 9:1-9. doi: 10.1080/00365521.2025.2487907.
    >> Share

    March 2025
  20. YOUNG JC, Helsingen LM, Refsum E, Hogden A, et al
    Temporal trends in characteristics and management of inflammatory bowel disease.
    Scand J Gastroenterol. 2025 Mar 24:1-9. doi: 10.1080/00365521.2025.2478166.
    >> Share

  21. EVERHOV AH, Eberhardson M, Soderling J, Nordenvall C, et al
    Cumulative incidence and prevalence of perianal diseases in patients with inflammatory bowel disease and in the population: a nationwide Swedish study.
    Scand J Gastroenterol. 2025 Mar 17:1-6. doi: 10.1080/00365521.2025.2476669.
    >> Share

  22. RASMUSSEN MS, Hansen LO, Deding U, Ellebaek MB, et al
    Applicability of colon capsule endoscopy for monitoring ulcerative colitis: a systematic review.
    Scand J Gastroenterol. 2025 Mar 14:1-7. doi: 10.1080/00365521.2025.2475081.
    >> Share

    January 2025
  23. BERGEMALM D, Baban B, Ljungqvist O, Halfvarson J, et al
    Insulin sensitivity in moderately severe to acute severe ulcerative colitis.
    Scand J Gastroenterol. 2025 Jan 30:1-5. doi: 10.1080/00365521.2025.2459870.
    >> Share

  24. RASMUSSEN MH, Brodersen JB, Brasen CL, Madsen JS, et al
    The diagnostic accuracy of plasma and serum calprotectin is inferior to C-reactive protein in patients with suspected Crohn's disease.
    Scand J Gastroenterol. 2025 Jan 29:1-8. doi: 10.1080/00365521.2025.2459236.
    >> Share

  25. HAMMER T, Agerbo Modin F, Rubek Nielsen K, Midjord J, et al
    Health-related quality of life at diagnosis and follow-up in Faroese and Danish patients with inflammatory bowel disease - a Faroese IBD cohort study.
    Scand J Gastroenterol. 2025 Jan 17:1-10. doi: 10.1080/00365521.2025.2453429.
    >> Share

  26. MUSTONEN A, Rankala R, Voutilainen M, Mattila K, et al
    The impact of IBD on ability to work and study: a patient perspective.
    Scand J Gastroenterol. 2025;60:37-41.
    >> Share

    November 2024
  27. YE YM, Wei MH, Lv KN, Xue XH, et al
    Effects of an anti-inflammatory diet (AID) on maternal and neonatal health outcomes in pregnant Chinese patients with inflammatory bowel disease treated with infliximab (IFX).
    Scand J Gastroenterol. 2024 Nov 9:1-9. doi: 10.1080/00365521.2024.2423828.
    >> Share

  28. DRUVEFORS E, Landerholm K, Andersson RE, Sydsjo G, et al
    Reasons for reduced reproduction after colectomy in women with ulcerative colitis.
    Scand J Gastroenterol. 2024 Nov 1:1-8. doi: 10.1080/00365521.2024.2416005.
    >> Share

    June 2024
  29. BONDE CHRISTIANSEN S, Ainsworth MA
    The role of chest X-rays when screening for latent tuberculosis infection in patients with inflammatory bowel disease before starting biologic treatment.
    Scand J Gastroenterol. 2024 Jun 22:1-7. doi: 10.1080/00365521.2024.2368248.
    >> Share

    May 2024
  30. CAMPO M, Hjelle H, Granlund AVB, Sandvik AK, et al
    The relationship between weight change and inflammatory bowel disease. A population-based cohort study, the HUNT study.
    Scand J Gastroenterol. 2024 May 13:1-5. doi: 10.1080/00365521.2024.2353099.
    >> Share

  31. HAMMOUDI N, Hassid D, Bonnet J, Tran Minh ML, et al
    Infliximab desensitization in patients with inflammatory bowel diseases: a safe therapeutic alternative.
    Scand J Gastroenterol. 2024;59:553-560.
    >> Share

    April 2024
  32. FORSS A, Flis P, Sotoodeh A, Kapraali M, et al
    Acute interstitial nephritis in patients with inflammatory bowel disease treated with vedolizumab: a systematic review.
    Scand J Gastroenterol. 2024 Apr 29:1-9. doi: 10.1080/00365521.2024.2345383.
    >> Share

  33. LARSEN L, Olesen AE, Nayeb AB, Grontved S, et al
    Beyond diagnosis: investigating hospital referral impact on biological treatment initiation, hospital admission, and surgery patterns in inflammatory bowel disease - a Danish population based study.
    Scand J Gastroenterol. 2024 Apr 3:1-8. doi: 10.1080/00365521.2024.2337829.
    >> Share

    March 2024
  34. KIASAT A, Prast-Nielsen S, Rautiainen S, Engstrand L, et al
    Plasma bile acids in association with Crohn's disease.
    Scand J Gastroenterol. 2024 Mar 20:1-9. doi: 10.1080/00365521.2024.2328592.
    >> Share

  35. RADFORD SJ, Abdul-Aema B, Tench C, Leighton P, et al
    Substantial cost savings of ultrasound-based management over magnetic resonance imaging-based management in an inflammatory bowel disease service.
    Scand J Gastroenterol. 2024 Mar 19:1-7. doi: 10.1080/00365521.2024.2330588.
    >> Share

  36. MERTZ NIELSEN A, Theede K, Gluud LL, Kiszka-Kanowitz M, et al
    Efficacy of optimised thiopurine therapy in patients with moderate-to-severe ulcerative colitis: retrospective long-term follow-up from two randomised trials.
    Scand J Gastroenterol. 2024 Mar 5:1-5. doi: 10.1080/00365521.2024.2323502.
    >> Share

  37. VIEUJEAN S, Gillard R, Delanaye P, Seidel L, et al
    Matrix gla protein, a potential marker of tissue remodelling and physiological ageing of the gut in crohn's disease.
    Scand J Gastroenterol. 2024;59:296-303.
    >> Share

    February 2024
  38. MIDJORD J, Nielsen KR, Vang AG, Strom M, et al
    Risk of malignancy in a high-incidence population-based cohort of Faroese patients with inflammatory bowel disease from 1960 to 2020 - a Faroese IBD cohort study.
    Scand J Gastroenterol. 2024 Feb 26:1-8. doi: 10.1080/00365521.2024.2320712.
    >> Share

  39. ZEROUGA I, Valeur J, Sommer C, Cvancarova Smastuen M, et al
    Dietary intake and nutritional status in patients with newly diagnosed inflammatory bowel disease: insights from the IBSEN III study.
    Scand J Gastroenterol. 2024 Feb 15:1-9. doi: 10.1080/00365521.2024.2313056.
    >> Share

    January 2024
  40. MALIK S, Loganathan P, Mohan BP
    Letter to editor: effects of vancomycin in primary sclerosing cholangitis with and without inflammatory bowel disease.
    Scand J Gastroenterol. 2024 Jan 30:1-2. doi: 10.1080/00365521.2024.2310168.
    >> Share

  41. THUNBERG J, Granno O, Bergemalm D, Eriksson C, et al
    Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels.
    Scand J Gastroenterol. 2024;59:150-155.
    >> Share

    December 2023
  42. MOLANDER P, Kosunen M, Eronen H, Tillonen J, et al
    Tofacitinib real-world experience in ulcerative colitis in Finland (FinTofUC): a retrospective non-interventional multicenter patient chart data study.
    Scand J Gastroenterol. 2023 Dec 29:1-8. doi: 10.1080/00365521.2023.2298361.
    >> Share

  43. STRAATMIJER T, van den Akker-van Marle ME, Ponsioen CY, van der Horst D, et al
    Patient preferences in treatment options of ulcerative colitis: a discrete choice experiment.
    Scand J Gastroenterol. 2023 Dec 2:1-8. doi: 10.1080/00365521.2023.2286191.
    >> Share

    November 2023
  44. HARNO-TASIHIN J, Siregar L, Paajanen M, Arkkila P, et al
    Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses.
    Scand J Gastroenterol. 2023 Nov 25:1-8. doi: 10.1080/00365521.2023.2285229.
    >> Share

  45. ZHANG Y, Jiang W, Xu C, Tian J, et al
    The impact of proactive versus reactive drug monitoring of infliximab on treatment outcomes in patients with crohn's disease.
    Scand J Gastroenterol. 2023 Nov 22:1-11. doi: 10.1080/00365521.2023.2283387.
    >> Share

  46. ANJIE SI, Hanzel J, Gecse KB, D'Haens GR, et al
    Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies.
    Scand J Gastroenterol. 2023 Nov 14:1-7. doi: 10.1080/00365521.2023.2278424.
    >> Share

  47. IBORRA M, Ferreiro-Iglesias R, Maria Dolores MA, Mesonero Gismero F, et al
    Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort.
    Scand J Gastroenterol. 2023 Nov 6:1-9. doi: 10.1080/00365521.2023.2278427.
    >> Share

    October 2023
  48. WANG L, Zhang Y, Wu H, Tang Z, et al
    Intestinal ultrasound score predicts therapeutic outcomes of infliximab in pediatric patients with Crohn's disease.
    Scand J Gastroenterol. 2023 Oct 31:1-8. doi: 10.1080/00365521.2023.2271110.
    >> Share

  49. NURMI E, Rantanen A, Paavilainen E, Haapamaki J, et al
    A quality assessment of inflammatory bowel disease nursing care in Finland: a nationwide cross-sectional descriptive study.
    Scand J Gastroenterol. 2023 Oct 30:1-5. doi: 10.1080/00365521.2023.2276654.
    >> Share

  50. YAN Q, Feng Z, Jiang B, Yao J, et al
    Biological functions of connexins in the development of inflammatory bowel disease.
    Scand J Gastroenterol. 2023 Oct 14:1-8. doi: 10.1080/00365521.2023.2267713.
    >> Share

    September 2023
  51. FOSSMARK R, Lirhus SS, Hoivik ML
    The impact of proton pump inhibitors on the course of ulcerative colitis: a cohort study of over 10,000 newly diagnosed patients in Norway.
    Scand J Gastroenterol. 2023 Sep 8:1-6. doi: 10.1080/00365521.2023.2255710.
    >> Share

    August 2023
  52. RANKALA R, Mustonen A, Voutilainen M, Mattila K, et al
    Costs of medications used to treat inflammatory bowel disease.
    Scand J Gastroenterol. 2023 Aug 29:1-5. doi: 10.1080/00365521.2023.2248539.
    >> Share

  53. ZHANG X, Wang P, Yang Y, Gao X, et al
    Monocyte/macrophage mediates the impact of depression on Crohn's disease.
    Scand J Gastroenterol. 2023 Aug 27:1-11. doi: 10.1080/00365521.2023.2245938.
    >> Share

  54. CHEN Y, Sun Z, Li Z, Duan M, et al
    Comparison of endoscopic balloon dilation and surgery for duodenal stricture in patients with Crohn's disease.
    Scand J Gastroenterol. 2023 Aug 25:1-7. doi: 10.1080/00365521.2023.2250495.
    >> Share

  55. CHEN C, Lan B, Xie G, Liu Z, et al
    Analysis and identification of ferroptosis-related genes in ulcerative colitis.
    Scand J Gastroenterol. 2023 Aug 2:1-12. doi: 10.1080/00365521.2023.2240927.
    >> Share

    July 2023
  56. KIM J, Jung JH, Jo H, Kim MH, et al
    Risk of uterine cervical cancer in inflammatory bowel disease: a systematic review and meta-analysis.
    Scand J Gastroenterol. 2023 Jul 30:1-10. doi: 10.1080/00365521.2023.2238101.
    >> Share

  57. BRODERSEN JB, Jensen MD, Juel MA, Kjeldsen J, et al
    Intestinal ultrasound in patients with suspected Crohn's disease - results of a prospective evaluation by trainees.
    Scand J Gastroenterol. 2023 Jul 17:1-7. doi: 10.1080/00365521.2023.2234538.
    >> Share

  58. BARNER-RASMUSSEN N, Sjoblom N, Arola J, Boyd S, et al
    The role of serology, liver function tests and imaging in screening of primary sclerosing cholangitis: the HelPSCreen score.
    Scand J Gastroenterol. 2023 Jul 14:1-8. doi: 10.1080/00365521.2023.2233038.
    >> Share

  59. MARK-CHRISTENSEN A, Jolving LR, Anru PL, Murray JA, et al
    A population-based nationwide study on total colectomy for ulcerative colitis and risk of ten prevalent inflammatory or autoimmune diseases.
    Scand J Gastroenterol. 2023 Jul 6:1-7. doi: 10.1080/00365521.2023.2231586.
    >> Share

  60. KATO I, Minkevitch J, Sun J
    Oncogenic potential of Campylobacter infection in the gastrointestinal tract: narrative review.
    Scand J Gastroenterol. 2023;58:1453-1465.
    >> Share

    June 2023
  61. BANZRAGCH M, Sanli K, Stensvold CR, Kurt O, et al
    Metabarcoding of colonic cleansing fluid reveals unique bacterial members of mucosal microbiota associated with Inflammatory Bowel Disease.
    Scand J Gastroenterol. 2023 Jun 20:1-11. doi: 10.1080/00365521.2023.2223708.
    >> Share

  62. FOLLIN-ARBELET B, Smastuen MC, Hovde O, Jelsness-Jorgensen LP, et al
    Incidence of cancer in patients with ulcerative colitis 30 years after diagnosis (the IBSEN study).
    Scand J Gastroenterol. 2023 Jun 20:1-7. doi: 10.1080/00365521.2023.2223709.
    >> Share

  63. KIASAT A, Rautiainen S, Prast-Nielsen S, Engstrand L, et al
    Evaluation of plasma Short chain fatty acid levels as markers for Inflammatory bowel disease.
    Scand J Gastroenterol. 2023 Jun 5:1-7. doi: 10.1080/00365521.2023.2219357.
    >> Share

    May 2023
  64. BEYSENS S, Wellens J, De Hertogh G, Van Laethem A, et al
    Managing metastatic Crohn's disease: a single center experience, review of the current evidence, and treatment algorithm.
    Scand J Gastroenterol. 2023 May 13:1-9. doi: 10.1080/00365521.2023.2209689.
    >> Share

  65. KIM KW, Koh SJ, Kang HW, Park H, et al
    Atopic dermatitis is associated with the clinical course of inflammatory bowel disease.
    Scand J Gastroenterol. 2023 May 11:1-7. doi: 10.1080/00365521.2023.2209688.
    >> Share

  66. SHI T, Liu W, Li T, Liu H, et al
    HLA-DQ genotype distribution and risk evaluation of celiac disease in Northwest China.
    Scand J Gastroenterol. 2023;58:471-476.
    >> Share

    April 2023
  67. LIU C, Zhan S, Li N, Tu T, et al
    Bile acid alterations associated with indolent course of inflammatory bowel disease.
    Scand J Gastroenterol. 2023 Apr 18:1-10. doi: 10.1080/00365521.2023.2200518.
    >> Share

  68. ZHU M, Fan L, Han M, Zhu S, et al
    The usefulness of fecal hemoglobin and calprotectin tests in diagnosing significant bowel diseases: a prospective study.
    Scand J Gastroenterol. 2023;58:368-374.
    >> Share

  69. KRIDIN K, Goral D, Shihade W, Tzur-Bitan D, et al
    Vitiligo and Crohn's disease form an autoimmune cluster: insights from a population-based study.
    Scand J Gastroenterol. 2023;58:354-359.
    >> Share

    March 2023
  70. PAUWELS RWM, Ten Bokkel Huinink S, van der Woude CJ, Doukas M, et al
    Early fecal calprotectin levels at week 8 may guide therapeutic decisions on Ustekinumab therapy in patients with Crohn's disease.
    Scand J Gastroenterol. 2023 Mar 27:1-8. doi: 10.1080/00365521.2023.2194009.
    >> Share

  71. LIU Y, Ji X, Huang Y, Li Q, et al
    Older patients benefit more from sequential courses of washed microbiota transplantation than younger population with ulcerative colitis.
    Scand J Gastroenterol. 2023 Mar 2:1-10. doi: 10.1080/00365521.2023.2185476.
    >> Share

    February 2023
  72. PAN Y, Huang X, Zhou Z, Yang X, et al
    Clinical significance of a novel uric-acid-based biomarker in the prediction of disease activity and response to infliximab therapy in Crohn's disease.
    Scand J Gastroenterol. 2023 Feb 24:1-7. doi: 10.1080/00365521.2023.2175181.
    >> Share

    November 2021
  73. WANG S, Zhang YR, Yu YB
    The important role of fungi in inflammatory bowel diseases.
    Scand J Gastroenterol. 2021;56:1312-1322.
    >> Share

    October 2021
  74. ALIPOUR O, Lee V, Tejura TK, Wilson ML, et al
    The assessment of sarcopenia using psoas muscle thickness per height is not predictive of post-operative complications in IBD.
    Scand J Gastroenterol. 2021;56:1175-1181.
    >> Share

  75. PRIMAS C, Hopf G, Reinisch S, Baumann L, et al
    Role of fecal calprotection in predicting endoscopic recurrence in postoperative Crohn's disease.
    Scand J Gastroenterol. 2021;56:1169-1174.
    >> Share

    September 2021
  76. LI Y, Pan J, Zhou N, Fu D, et al
    A random forest model predicts responses to infliximab in Crohn's disease based on clinical and serological parameters.
    Scand J Gastroenterol. 2021;56:1030-1039.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016